These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20633187)

  • 1. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
    Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
    Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
    Lee VW; Chau TS; Chan AK; Lee KK; Waye MM; Ling TK; Chan FK
    J Clin Pharm Ther; 2010 Jun; 35(3):343-50. PubMed ID: 20831535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
    Hsu PI; Wu DC; Chen A; Peng NJ; Tseng HH; Tsay FW; Lo GH; Lu CY; Yu FJ; Lai KH
    Eur J Clin Invest; 2008 Jun; 38(6):404-9. PubMed ID: 18435764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
    Zhang L; Mei Q; Li QS; Hu YM; Xu JM
    J Clin Pharm Ther; 2010 Dec; 35(6):713-22. PubMed ID: 21054464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
    Kuo CH; Hu HM; Kuo FC; Hsu PI; Chen A; Yu FJ; Tsai PY; Wu IC; Wang SW; Li CJ; Weng BC; Chang LL; Jan CM; Wang WM; Wu DC
    J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
    Wu IC; Wu DC; Hsu PI; Lu CY; Yu FJ; Wang TE; Chang WH; Chen JJ; Kuo FC; Wu JY; Wang WM; Bair MJ
    Helicobacter; 2007 Dec; 12(6):633-7. PubMed ID: 18001406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
    Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
    Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
    Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
    Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
    Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.